Lv5
970 积分 2024-07-09 加入
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study
10天前
已完结
Epidemiology of liver diseases: global disease burden and forecasted research trends
18天前
已完结
T cell dynamics with neoadjuvant immunotherapy in head and neck cancer
6个月前
已完结
Different biliary tract cancers, same operation: Importance of cancer origin in patients with hilar-invading tumors
10个月前
已完结
Development and validation of nomograms to evaluate the survival outcome of HCC patients undergoing selective postoperative adjuvant TACE
1年前
已完结
皖公网安备34019202002308
